Roll-Out Across National Bioskills Training Centers Gives Med Device Companies and Surgeons Access to Intelligent Data-Driven Technology Platform and AI Learning Roll-Out Across National Bioskills Training Centers Gives Med Device Companies and Surgeons Access to Intelligent Data-Driven Technology Platform and AI Learning

Read more:
OMNIMED™ Announces Integration of SmartOR™ Into Axis Research & Technologies Facilities

Clinical Trial Focuses on Assessing Whether LB-100 Enhances the Effectiveness of a Standard Regimen Combining Immunotherapy and Chemotherapy for Untreated Small Cell Lung Cancer as it Does in Animal Models

Link:
LIXTE Biotechnology Announces Sarah Cannon Research Institute Joins City of Hope’s Ongoing Phase 1b Clinical Trial in Evaluating Lixte’s Lead...

Preliminary data of Ampligen seen to date demonstrates potential to be an effective treatment option for post-COVID conditions Preliminary data of Ampligen seen to date demonstrates potential to be an effective treatment option for post-COVID conditions

Read this article:
AIM ImmunoTech Announces Central IRB Approval of Phase 2 Study Protocol Evaluating Ampligen® for the Treatment of Post-COVID Conditions

MALVERN, Pa., April 04, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, today provided a corporate update which includes entering into a new credit facility with investment affiliates managed by SLR Capital Partners, LLC (“SLR”) and providing Greenbrook TMS (“Greenbrook”) with a promissory note as part of an updated TMS device supply agreement.

Here is the original post:
Neuronetics Secures Up To $60 Million in New Debt Financing with SLR Capital Partners, Provides Greenbrook TMS with $6.0 Million Promissory Note

Over 90% of the shares voted to date have shown support “FOR” each of the five proposals, but additional votes are needed in order to close the proposed merger with GRI Bio

View post:
Vallon Pharmaceuticals Provides an Update on Proxy Voting for the Proposed Merger with GRI Bio and Urges Stockholders of Record as of March 6, 2023 to...

FLORHAM PARK, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic cell therapies and biomaterial products, announced today an oral and poster presentation at the upcoming 2023 Annual Meeting Society for Biomaterials (“SFB”), which will be held April 19th – 22nd in San Diego, CA. The oral presentation and poster highlights the role decellularized dehydrated human amniotic membranes plays in supporting human tenocytes in vitro.

Continue reading here:
Celularity Announces Acceptance of Poster Presentation at 2023 Society for Biomaterials Annual Meeting

FORT WORTH, TX, April 04, 2023 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today that it has received 510(k) clearance for BIASURGE™ Advanced Surgical Solution (“BIASURGE™").

See more here:
Sanara MedTech Inc. Announces 510(k) Clearance for BIASURGE™ Advanced Surgical Solution

The Company strengthens its analytical R&D capabilities,to better support its customers operating in the CDMO and Generics market.

Read more:
Dipharma expands its Italian R&D Center to increase its analytical services

Martinsried/Munich, April 04, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard) is an early-stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors. Prof. Dr. Dolores Schendel, Medigene‘s Chief Scientific Officer, has been invited to present at the 4th TCR-based Therapies for Solid Tumors Summit in Boston on April 04, 2023. The title of her presentation will be “Case Study Spotlight: Introducing Innovations at Each Step of TCR Therapy Development”.

Go here to read the rest:
Medigene AG Presents Systematic and Sequential, End-To-End Platform Approach to Optimize TCR-T Therapy Development

NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that Dr. Saef Izzy will present pre-clinical data on the effects of intranasal anti-CD3 monoclonal antibody in an animal model of intracerebral hemorrhage (hemorrhagic stroke) on April 23, 2023, at 2:48 PM at Neurocritical Care Scientific Platform Session at the prestigious Annual American Academy of Neurology (AAN) conference in Boston, MA.

See the original post here:
Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual...

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced that Negma Group (“Negma”) has by notice to Mendus requested the conversion of convertible bonds that have been issued to Negma in accordance with the financing agreement announced by Mendus through press releases on 26 August and 26 October 2022.

Read the original here:
Mendus announces request for conversion of convertible bonds by Negma Group

MORRISVILLE, N.C., April 04, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced Jeanine O’Kane as President of Syneos Health Communications — a portfolio of agencies spanning advertising, public relations, patient advocacy, medical communications, managed markets, and naming and branding. Formally President of the US Public Relations Group at Syneos Health Communications, Jeanine has been with the organization for more than a decade and has more than 20 years of industry experience.

Continue reading here:
Syneos Health Names Jeanine O’Kane as Communications President

PRESS RELEASE

Link:
AB Science announces that it has submitted its response to the day 120 questions in the EMA regulatory review of masitinib in amyotrophic lateral...

TORONTO, April 04, 2023 (GLOBE NEWSWIRE) -- Axiom Real-Time Metrics ("Axiom"), a premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations, will be exhibiting at Clinical Trial Supply New England 2023, April 5-6 in Boston, Massachusetts.

See the article here:
Axiom Exhibiting at Clinical Trial Supply New England 2023

MONT-SAINT-GUIBERT, Belgium, April 04, 2023 (GLOBE NEWSWIRE) -- Celyad Oncology (Euronext & Nasdaq: CYAD) (the “Company”), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, received a letter (the “Letter”) on March 31, 2023 from The Nasdaq Stock Market (“Nasdaq”) informing the Company that it failed to maintain the continued listing requirement under Nasdaq Listing Rule 5450(b)(1)(A) for the Nasdaq Global Market, which requires that a listed company’s stockholders’ equity be at least $10.0 million (the “Stockholders’ Equity Requirement”).

Go here to read the rest:
Celyad Oncology announces receipt of Nasdaq notice

JENA, Germany, April 04, 2023 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced that Gohibic (vilobelimab), a first-in-class monoclonal anti-human complement factor C5a antibody, has been granted an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the treatment of coronavirus disease 19 (COVID-19) in hospitalized adults when initiated within 48 hours of receiving invasive mechanical ventilation (IMV), or extracorporeal membrane oxygenation (ECMO).

Excerpt from:
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 Patients

HOUSTON, April 04, 2023 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biopharmaceutical company using protein inhibition and protein degradation to develop cancer therapies for patients in need of new treatment options, today announced that management will present at the Diamond Equity Research Emerging Growth Invitational virtual investor conference taking place Wednesday, April 5th.

Read this article:
Salarius Pharmaceuticals to Present at the Diamond Equity Research Emerging Growth Invitational Conference

REDWOOD CITY, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that Patrick Yang, PhD, will not seek re-election to the Codexis Board of Directors. Dr. Yang joined the Board in 2014 and served as the Chair of the Nominating and Corporate Governance Committee.

Go here to see the original:
Codexis Announces Decision of Patrick Yang, PhD, Not to Seek Re-Election to Board of Directors

NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies today announced that the Company entered into the warrant agreement (the “Warrant Agreement”) and finalized the related ancillary documents required under the credit facility with the European Investment Bank (“EIB”) (the "Finance Contract") for up to €40 million previously announced on December 28, 2022. The Company also announced the drawdown of the first tranche of €20 million (“Tranche A”) under the Finance Contract, expected to be disbursed by the EIB in early April 2023. The Company plans to use the proceeds of Tranche A towards the development of its pipeline of allogeneic CAR T-cell product candidates: UCART22, UCART20x22, UCART123 and UCARTCS1.

More:
Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first...

EMERYVILLE, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced multiple presentations at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023), taking place April 15-18, 2023 in Copenhagen, Denmark. Both presentations are from the company’s CORAL program, which is evaluating various self-amplifying mRNA (samRNA) vaccine candidates targeting Spike in addition to other viral genes of SARS-CoV-2. The program aims to serve as proof-of-concept for Gritstone’s infectious disease vaccine approach and the potential application of samRNA against infectious diseases.

See original here:
Gritstone bio Announces Presentations Evaluating Self-amplifying mRNA (samRNA) Against SARS-CoV-2 at ECCMID 2023